Lineage Cell Therapeutics Inc (LCTX)

[hutschi]

Lineage Cell Therapeutics to Present at the 13th Annual LD Micro Main Event Conference on December 14, 2020 - Business Wire

09-Dec-2020 14:00:07CA-LINEAGE-CELL

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201209:nBw140kxFa&default-theme=true


Lineage Cell Therapeutics to Present at the 13(th) Annual LD Micro Main Event
Conference on December 14, 2020

Lineage Cell Therapeutics, Inc.
(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lineagecell.com%2F&esheet=52345270&newsitemid=20201209005296&lan=en-US&anchor=Lineage+Cell+Therapeutics%2C+Inc.&index=1&md5=50ddf8c0c73df1635b8348608d2d1ae3)
(NYSE American and TASE: LCTX), a clinical-stage biotechnology company
developing three novel cell therapies for serious medical conditions, today
announced that Brian M. Culley, Chief Executive Officer, will be presenting at
the 13(th) Annual LD Micro Main Event
(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fve.mysequire.com%2F&esheet=52345270&newsitemid=20201209005296&lan=en-US&anchor=13th+Annual+LD+Micro+Main+Event&index=2&md5=e0c5b9e7285106e6aff34143d96bf328)
virtual conference on December 14, 2020 at 12:00 pm Eastern Time / 9:00am
Pacific Time. Interested investors can register and access the live
presentation on the 13(th) Annual LD Micro Main Event
(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fve.mysequire.com%2F&esheet=52345270&newsitemid=20201209005296&lan=en-US&anchor=13th+Annual+LD+Micro+Main+Event&index=3&md5=6fefe7affdc89241560b963ffd30ea54)
conference page as well as on the Events and Presentations
(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.lineagecell.com%2Fevents-and-presentations%2Fupcoming-events&esheet=52345270&newsitemid=20201209005296&lan=en-US&anchor=Events+and+Presentations&index=4&md5=5197c93132342fdcdec5ad55b2b4e95d)
section of Lineage’s website.

The archived presentation will be available on the Events and Presentations
(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.lineagecell.com%2Fevents-and-presentations%2Fupcoming-events&esheet=52345270&newsitemid=20201209005296&lan=en-US&anchor=Events+and+Presentations&index=5&md5=4512e2e1c21a27ddfd06ab1646b0a063)
section of Lineage’s website for 30 days. Additional videos are available on
the Media page of the Lineage website, located at www.lineagecell.com/media/
(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lineagecell.com%2Fmedia%2F&esheet=52345270&newsitemid=20201209005296&lan=en-US&anchor=www.lineagecell.com%2Fmedia%2F&index=6&md5=46a6ea7b141aeebb6484a45148854ff2)
.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing
novel cell therapies for unmet medical needs. Lineage’s programs are based
on its robust proprietary cell-based therapy platform and associated in-house
development and manufacturing capabilities. With this platform Lineage
develops and manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support cells that are
dysfunctional or absent due to degenerative disease or traumatic injury or
administered as a means of helping the body mount an effective immune response
to cancer. Lineage’s clinical programs are in markets with billion dollar
opportunities and include three allogeneic (“off-the-shelf”) product
candidates: (i) OpRegen(®), a retinal pigment epithelium transplant therapy
in Phase 1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world; (ii) OPC1,
an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the
treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic
dendritic cell therapy platform for immuno-oncology and infectious disease,
currently in clinical development for the treatment of non-small cell lung
cancer. For more information, please visit www.lineagecell.com
(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lineagecell.com&esheet=52345270&newsitemid=20201209005296&lan=en-US&anchor=www.lineagecell.com&index=7&md5=a799a6f5e65f54a7808e75cef60a408d)
or follow the Company on Twitter @LineageCell
(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FLineageCell&esheet=52345270&newsitemid=20201209005296&lan=en-US&anchor=%40LineageCell&index=8&md5=1024bdf10604bcd183c4878bbaad6e5f)
.



View source version on businesswire.com:
https://www.businesswire.com/news/home/20201209005296/en/
(https://www.businesswire.com/news/home/20201209005296/en/)

Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone

([e-mail] (mailto:[e-mail]) )

[phone]

Solebury Trout IR

Gitanjali Jain Ogawa

([e-mail] (mailto:[e-mail]) )

[phone]

Russo Partners – Media Relations

Nic Johnson or David Schull

[e-mail]
(mailto:[e-mail])
[e-mail]
(mailto:[e-mail])
[phone]


Copyright Business Wire 2020Copyright Business Wire 2020

nBw140kxFa
----------


(C) Refinitiv 2020. All rights reserved. The Refinitiv content received through this service is the intellectual property of Refinitiv or its third party suppliers. Republication or redistribution of content provided by Refinitiv is expressly prohibited without the prior written consent of Refinitiv, except where permitted by the terms of the relevant Refinitiv service agreement. Neither Refinitiv nor its third party suppliers shall be liable for any errors, omissions or delays in content, or for any actions taken in reliance thereon. Refinitiv and its logo are trademarks or trademarks of the Refinitiv group of companies around the world.